How to buy Exelixis stock (EXEL)

Exelixis (EXEL) is a leading biotechnology business based in the US. It opened the day at $28.48 after a previous close of $27.87. During the day the price has varied from a low of $28.30 to a high of $28.98. The latest price was $28.73 (25 minute delay). Exelixis is listed on the NASDAQ and employs 1,310 staff. All prices are listed in US Dollars.

Our top picks for where to buy Exelixis stock

Buy Exelixis stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Exelixis stock price (NASDAQ: EXEL)

Use our graph to track the performance of EXEL stocks over time.

Exelixis shares at a glance

• Live prices
• Key figures

Information last updated 2024-10-15.

Open	$26.30
High	$28.66
Low	$26.06
Close	$28.10
Previous close	$26.24
Change more info button	$1.86
Change % more info button	7.0884%
Volume more info button	3,072,653

Information last updated 2024-10-24.

52-week range	$19.20 - $29.75
50-day moving average more info button	$26.55
200-day moving average more info button	$23.45
Wall St. target price	$29.80
PE ratio more info button	24.2328
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$1.16

Is it a good time to buy Exelixis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Exelixis price performance over time

Historical closes compared with the close of $28.73 from 2024-10-25

1 week (2024-10-22)	-0.35%
1 month (2024-09-30)	10.71%
3 months (2024-07-30)	23.46%
6 months (2024-04-30)	22.46%

1 year (2023-10-30)	41.95%
2 years (2022-10-28)	72.76%
3 years (2021-10-29)	33.57%
5 years (2019-10-30)	65.30%

Is Exelixis stock undervalued or overvalued?

Valuing Exelixis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Exelixis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Exelixis's P/E ratio

Exelixis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Exelixis shares trade at around 24x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Exelixis's PEG ratio

Exelixis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.2372. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Exelixis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Exelixis's EBITDA

Exelixis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $429.4 million.

The EBITDA is a measure of a Exelixis's overall financial performance and is widely used to measure a its profitability.

Exelixis financials

Revenue TTM	$2 billion
Operating margin TTM	43.37%
Gross profit TTM	$1.6 billion
Return on assets TTM	8.51%
Return on equity TTM	15.06%
Profit margin	17.38%
Book value	$7.43
Market Capitalization more info button	$8 billion

TTM: trailing 12 months

Exelixis share dividends

We're not expecting Exelixis to pay a dividend over the next 12 months.

Exelixis share price volatility

Over the last 12 months, Exelixis's shares have ranged in value from as little as $19.2 up to $29.7499. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exelixis's is 0.541. This would suggest that Exelixis's shares are less volatile than average (for this exchange).

Exelixis overview

Exelixis, Inc. , an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.

Frequently asked questions

null
What percentage of Exelixis is owned by insiders or institutions?
Currently 1.718% of Exelixis shares are held by insiders and 87.279% by institutions. How many people work for Exelixis?
Latest data suggests 1,310 work at Exelixis. When does the fiscal year end for Exelixis?
Exelixis's fiscal year ends in December. Where is Exelixis based?
Exelixis's address is: 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502 What is Exelixis's ISIN number?
Exelixis's international securities identification number is: US30161Q1040 What is Exelixis's CUSIP number?
Exelixis's Committee on Uniform Securities Identification Procedures number is: 30161Q104